Editorial Commentary
Editorial: early PSA-testing after radical prostatectomy—the truth behind the scenes
Abstract
Adequate treatment of localized prostate cancer (PCa) remains challenging. Data from the U.S. National Cancer Institute reveals that PCa accounts for 9.9% of all new cancer diagnoses and 5.2% of all cancer deaths, accounting for 174,650 new cases and 31,620 deaths in 2019 (1). This data shows still a definite necessity for wide-ranging diagnostic, treatment, and follow-up options.